Literature DB >> 33602169

Clinical outcomes of bulky parotid gland cancers: need for self-examination and screening program for early diagnosis of parotid tumors.

Sung Yong Choi1, Eunkyu Lee1, Eunhye Kim1, Man Ki Chung1, Young-Ik Son1, Chung-Hwan Baek1, Han-Sin Jeong2.   

Abstract

BACKGROUND: Early detection and diagnosis of parotid gland cancer (PGC) are essential to improve clinical outcomes, because Tumor-Node-Metastasis stage at diagnosis is a very strong indicator of prognosis in PGC. Nevertheless, some patients still present with large parotid mass, maybe due to the unawareness or ignorance of their disease. In this study, we aimed to present the clinical outcomes of bulky PGC (defined by a 4 cm cutoff point for T3-4 versus T1-2 tumors), to emphasize the necessity of a self-examination tool for parotid gland tumor.
METHODS: We retrospectively reviewed 60 consecutive cases with bulky (equal to and greater than 4 cm in the longest diameter, determined radiologically) malignant tumors arising from the parotid gland from 1995 to 2016. The clinical and pathological factors were analyzed to identify risk factors for poor outcomes using Cox proportional hazard models. In addition, we designed a self-examination tool for parotid gland tumors, similar to breast self-examination for breast cancer detection.
RESULTS: Patients with bulky parotid cancer showed 48.9% 5-year and 24.5% 10-year overall survival rates and a 47.9% risk of high-grade malignancy. The common pathological diagnoses were carcinoma ex pleomorphic adenoma (18.3%), adenocarcinoma (16.7%), mucoepidermoid carcinoma (16.7%), salivary duct carcinoma (16.7%), and adenoid cystic carcinoma (11.7%). Survival analyses revealed that tumor size (hazard ratio, HR = 1.262 upon increase of 1 cm, 95% confidence interval, 95%CI 1.059-1.502), lymph node metastasis (HR = 2.999, 95%CI 1.048-8.583), and high tumor grade (HR = 4.148, 95%CI 1.215-14.154) were independent prognostic factors in multivariable analysis. Functional preservation of the facial nerve was possible only in less than half of patients.
CONCLUSION: In bulky PGC, lymph node metastasis at diagnosis and high tumor grade indicated poor survival outcomes, and functional outcomes of the facial nerve were suboptimal. Thus, a public effort seems to be necessary to decrease these patients with bulky PGC, and to increase patients' self-awareness of their disease. As a way of early detection, we proposed a parotid self-examination tool to detect parotid gland tumors at an early stage, which is similar to breast self-examination.

Entities:  

Keywords:  Advanced stage, prognosis; Parotid gland; Surgery; Tumor

Mesh:

Year:  2021        PMID: 33602169      PMCID: PMC7890841          DOI: 10.1186/s12885-021-07902-9

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  26 in total

Review 1.  Electrophysiologic facial nerve monitoring during parotidectomy.

Authors:  David W Eisele; Steven J Wang; Lisa A Orloff
Journal:  Head Neck       Date:  2010-03       Impact factor: 3.147

2.  Tumours of the parotid gland: the significance of tumour size and facial nerve involvement.

Authors:  A A El-Domeiri; S Khan
Journal:  Clin Oncol       Date:  1979-03

3.  Facial nerve function after partial superficial parotidectomy: An 11-year review (1987-1997).

Authors:  R L Witt
Journal:  Otolaryngol Head Neck Surg       Date:  1999-09       Impact factor: 3.497

4.  Parotid tumor size predicts proximity to the facial nerve.

Authors:  Natalie A Domenick; Jonas T Johnson
Journal:  Laryngoscope       Date:  2011-11       Impact factor: 3.325

5.  Salivary duct carcinoma: Treatment, outcomes, and patterns of failure.

Authors:  Meredith L Johnston; Shao Hui Huang; John N Waldron; Eshetu G Atenafu; Kelvin Chan; Bernard J Cummings; Ralph W Gilbert; David Goldstein; Patrick J Gullane; Jonathan C Irish; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Bayley; John Cho; Laura A Dawson; Andrew Hope; Jolie Ringash; Ian J Witterick; Brian O'Sullivan; John Kim
Journal:  Head Neck       Date:  2015-07-15       Impact factor: 3.147

6.  Carcinoma of the parotid gland.

Authors:  Peter Zbären; Jonas Schüpbach; Michel Nuyens; Edouard Stauffer; Richard Greiner; Rudolf Häusler
Journal:  Am J Surg       Date:  2003-07       Impact factor: 2.565

7.  Breast self-examination practices and breast-cancer stage.

Authors:  R S Foster; S P Lang; M C Costanza; J K Worden; C R Haines; J W Yates
Journal:  N Engl J Med       Date:  1978-08-10       Impact factor: 91.245

8.  Estimated effect of breast self-examination and routine physician examinations on breast-cancer mortality.

Authors:  P Greenwald; P C Nasca; C E Lawrence; J Horton; R P McGarrah; T Gabriele; K Carlton
Journal:  N Engl J Med       Date:  1978-08-10       Impact factor: 91.245

9.  Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands.

Authors:  Safina Ali; Frank L Palmer; Changhong Yu; Monica DiLorenzo; Jatin P Shah; Michael W Kattan; Snehal G Patel; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2013-10-17       Impact factor: 5.344

10.  Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2 N0 high-grade salivary gland cancer.

Authors:  Jeon Yeob Jang; Nayeon Choi; Young-Hyeh Ko; Man Ki Chung; Young-Ik Son; Chung-Hwan Baek; Kwan-Hyuck Baek; Han-Sin Jeong
Journal:  BMC Cancer       Date:  2018-06-20       Impact factor: 4.430

View more
  2 in total

1.  Comparison of Different Machine Models Based on Multi-Phase Computed Tomography Radiomic Analysis to Differentiate Parotid Basal Cell Adenoma From Pleomorphic Adenoma.

Authors:  Yun-Lin Zheng; Yi-Neng Zheng; Chuan-Fei Li; Jue-Ni Gao; Xin-Yu Zhang; Xin-Yi Li; Di Zhou; Ming Wen
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

2.  Quantitative Analysis and Pathological Basis of Signal Intensity on T2-Weighted MR Images in Benign and Malignant Parotid Tumors.

Authors:  Peiying Wei; Chang Shao; Min Tian; Mengwei Wu; Haibin Wang; Zhijiang Han; Hongjie Hu
Journal:  Cancer Manag Res       Date:  2021-07-07       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.